CD38-targeted and erythrocyte membrane camouflaged nanodrug delivery system for photothermal and chemotherapy in multiple myeloma.

Autor: Zhang F; Department of Hematology, The Third Xiangya Hospital, Central South University, Changsha 410013, People's Republic of China., Yang Q; Department of Hematology, The Third Xiangya Hospital, Central South University, Changsha 410013, People's Republic of China., Tang S; Department of Hematology, The Third Xiangya Hospital, Central South University, Changsha 410013, People's Republic of China., Jiang S; Department of Hematology, The Third Xiangya Hospital, Central South University, Changsha 410013, People's Republic of China., Zhao Q; Department of Blood Transfusion, The Third Xiangya Hospital, Central South University, Changsha 410013, People's Republic of China., Li J; Department of Blood Transfusion, The Third Xiangya Hospital, Central South University, Changsha 410013, People's Republic of China., Xu C; Department of Hematology, The Third Xiangya Hospital, Central South University, Changsha 410013, People's Republic of China., Liu J; Department of Hematology, The Third Xiangya Hospital, Central South University, Changsha 410013, People's Republic of China. Electronic address: jingliu0318@aliyun.com., Fu Y; Department of Blood Transfusion, The Third Xiangya Hospital, Central South University, Changsha 410013, People's Republic of China. Electronic address: fuyunfeng@csu.edu.cn.
Jazyk: angličtina
Zdroj: International journal of pharmaceutics [Int J Pharm] 2023 Aug 25; Vol. 643, pp. 123241. Date of Electronic Publication: 2023 Jul 20.
DOI: 10.1016/j.ijpharm.2023.123241
Abstrakt: Multiple myeloma (MM) is a malignant and incurable disease. Chemotherapy is currently the primary treatment option for MM. However, chemotherapeutic drugs can interrupt treatment because of serious side effects. Therefore, development of novel therapeutics for MM is essential. In this study, we designed and constructed an innovative nanoparticle-based drug delivery system, P-R@Ni 3 P-BTZ, and investigated its feasibility, effectiveness, and safety both in vitro and in vivo. P-R@Ni 3 P-BTZ is a nanocomposite that consists of two parts: (1) the drug carrier (Ni 3 P), which integrates photothermal therapy (PTT) with chemotherapy by loading bortezomib (BTZ); and (2) the shell (P-R), a CD38 targeting peptide P-modified red blood cell membrane nanovesicles. In vitro and in vivo, it was proven that P-R@Ni 3 P-BTZ exhibits remarkable antitumor effects by actively targeting CD38 + MM cells. P-R@Ni 3 P-BTZ significantly induces the accumulation of intracellular reactive oxygen species (ROS) and increases the apoptosis of MM cells, which underlies the primary mechanism of its antitumor effects. In addition, P-R@Ni 3 P exhibits good biocompatibility and biosafety, both in vitro and in vivo. Overall, P-R@Ni 3 P-BTZ is a specific and efficient MM therapeutic method.
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: